Aberrant Crypt Foci: The Case for Inclusion as a Biomarker for Colon Cancer
AbstractAberrant crypt foci (ACF) are one of the earliest histopathological manifestations of colon cancer. In this review, we critically present the molecular, cellular, histopathological, and chemopreventive evidence that ACF are relevant biomarkers for colon cancer. The laboratory and clinical evidence are highly suggestive that ACF are in the pathway leading to colon cancer, but not all ACF will do so. The possible fate and outcome of ACF in the progression toward colon cancer may be dependent on a number of features that define their predictive power for the prevention or progression of cancer. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Wargovich, M.J.; Brown, V.R.; Morris, J. Aberrant Crypt Foci: The Case for Inclusion as a Biomarker for Colon Cancer. Cancers 2010, 2, 1705-1716.
Wargovich MJ, Brown VR, Morris J. Aberrant Crypt Foci: The Case for Inclusion as a Biomarker for Colon Cancer. Cancers. 2010; 2(3):1705-1716.Chicago/Turabian Style
Wargovich, Michael J.; Brown, Vondina R.; Morris, Jay. 2010. "Aberrant Crypt Foci: The Case for Inclusion as a Biomarker for Colon Cancer." Cancers 2, no. 3: 1705-1716.